Several trials have demonstrated that 30–50% of patients with refractory or relapsed acute myelogenous leukemia (AML) can achieve complete remission after receiving allogenic NK cells [16] stimulated with cytokines (typically IL-2 or IL-15) [103]. The gene discussed is IL15; the disease is acute myeloid leukemia.